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Introduction: The use of a system for continuous control of endotracheal tube cuff pressure reduced the incidence
of ventilator-associated pneumonia (VAP) in one randomized controlled trial (RCT) with 112 patients but not in another
RCT with 142 patients. In several guidelines on the prevention of VAP, the use of a system for continuous or
intermittent control of endotracheal cuff pressure is not reviewed. The objective of this study was to compare
the incidence of VAP in a large sample of patients (n = 284) treated with either continuous or intermittent control of
endotracheal tube cuff pressure.
Methods: We performed a prospective observational study of patients undergoing mechanical ventilation during
more than 48 hours in an intensive care unit (ICU) using either continuous or intermittent endotracheal tube cuff
pressure control. Multivariate logistic regression analysis (MLRA) and Cox proportional hazard regression analysis were
used to predict VAP. The magnitude of the effect was expressed as odds ratio (OR) or hazard ratio (HR), respectively,
and 95% confidence interval (CI).
Results: We found a lower incidence of VAP with the continuous (n = 150) than with the intermittent (n = 134) pressure
control system (22.0% versus 11.2%; p = 0.02). MLRA showed that the continuous pressure control system (OR = 0.45;
95% CI = 0.22-0.89; p = 0.02) and the use of an endotracheal tube incorporating a lumen for subglottic secretion
drainage (SSD) (OR = 0.39; 95% CI = 0.19-0.84; p = 0.02) were protective factors against VAP. Cox regression analysis
showed that the continuous pressure control system (HR = 0.45; 95% CI = 0.24-0.84; p = 0.01) and the use of an
endotracheal tube incorporating a lumen for SSD (HR = 0.29; 95% CI = 0.15-0.56; p < 0.001) were protective factors
against VAP. However, the interaction between type of endotracheal cuff pressure control system (continuous or
intermittent) and endotracheal tube (with or without SSD) was not statistically significant in MLRA (OR = 0.41; 95%
CI = 0.07-2.37; p = 0.32) or in Cox analysis (HR = 0.35; 95% CI = 0.06-1.84; p = 0.21).
Conclusions: The use of a continuous endotracheal cuff pressure control system and/or an endotracheal tube with a
lumen for SSD could help to prevent VAP in patients requiring more than 48 hours of mechanical ventilation.Introduction
Ventilator-associated pneumonia (VAP) continues to be
an important cause of morbidity and mortality in critic-
ally ill patients [1-6].
Tracheal tube cuff-pressure should be sufficiently high
to prevent leaks that could make mechanical ventilation
ineffective, and to prevent the progression of secretions* Correspondence: lorentemartin@msn.com
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reproduction in any medium, provided the orfrom the oropharynx towards the lower airway, in order to
reduce the appearance of VAP. In one study, patients with
persistently low tracheal-tube cuff pressure below 20 cm
H2O showed a higher incidence of VAP [7]. In this study, in-
cluding 83 intubated patients undergoing continuous sub-
glottic secretion drainage (SSD), the authors found that
patients with persistent intra-cuff pressures below 20 cm
H2O showed a trend towards a higher risk of VAP (relative
risk (RR) = 2.57, 95% CI = 0.78, 8.03), and a statistically sig-
nificant risk of VAP among patients not receiving antibiotics
(RR = 4.23, 95% CI = 1.12, 15.92). On the other hand,l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to avoid vascular compromise of the trachea, which could
result in tracheomalacia and even tracheal necrosis [8,9].
A preventive strategy to avoid the progression of sub-
glottic secretions into the lower respiratory tract is the
use of a system for continuous control of endotracheal-
tube cuff pressure. In one randomized controlled trial
(RCT) published in 2007, which included 142 mechanic-
ally ventilated patients, there were no significant differ-
ences in the incidence of VAP between groups treated
with a continuous or an intermittent endotracheal-tube
cuff-pressure control system [10]. However, another RCT
published in 2011, with 122 patients expected to receive
mechanical ventilation for at least 48 hours, found a lower
incidence of VAP with the use of a continuous compared
to an intermittent endotracheal-tube cuff-pressure control
system [11].
In several guidelines on the prevention of VAP, the
issue of endotracheal-tube cuff-pressure control is not
reviewed [12-15]. Other guidelines only recommend main-
taining optimal tube cuff-pressure but make no recom-
mendations on the use of a continuous or intermittent
tube cuff-pressure control system [16-19].
Thus, the objective of this research was to compare
the incidence of VAP in a large sample of mechanically
ventilated ICU patients receiving either a continuous or
an intermittent endotracheal-tube cuff-pressure control
system. We hypothesized that the use of a continuous
endotracheal cuff-pressure control system could help to
prevent VAP. We would have preferred to use an endo-
tracheal tube with a lumen for SSD in all patients as sev-
eral RCTs have shown that this reduced the incidence of
VAP [20-22], and furthermore, it has been recom-
mended in several guidelines [12-15,17-19]. However,
due to financial constraints, endotracheal tubes without
a lumen for SSD were used in some patients; precisely
because of this limitation, we were able to analyze the
impact of continuous control of cuff pressure and tube
with a lumen for SSD on the incidence of VAP.
Methods
Design of the study
A prospective observational study with an incidental
sample of 284 patients was performed at the 24-bed
medical-surgical ICU of the Hospital Universitario de
Canarias (Tenerife, Spain), a 650-bed tertiary hospital,
during one year. The study was approved by the Institu-
tional Review Board of the Hospital Universitario de
Canarias (Tenerife, Spain). Informed consent was ob-
tained from the patients or their legal guardians. The
inclusion and exclusion criteria were as follows: inclu-
sion - patients requiring mechanical ventilation; exclu-
sion - patients requiring mechanical ventilation for less
than 48 hours (as their risk of VAP is low).VAP prevention measures
Patients who were admitted to an odd-numbered ICU
cubicle received a continuous cuff-pressure system
(Mallinckrodt Pressure Control®; VBM Medizintech-
nik GmbH, Sulz am Neckar, Germany) and those ad-
mitted to an even-numbered ICU cubicle received an
intermittent cuff-pressure system (Mallinckrodt Pres-
sure Manometer®; Mallinckrodt, Athlone, Ireland). In
both patient groups, intra-cuff pressure was verified
every 8 hours to maintain it at 25 cm H2O and pres-
sure values were recorded in the chart of each patient.
Each type of cuff-pressure system was applied from the
beginning of connection to mechanical ventilation.
Endotracheal tubes used were Mallinckrodt™ Taper-
Guard Evac Oral Tracheal Tube (Covidien, Mansfield,
MA, USA) which incorporates a taper-shaped cuff of
polyvinylchloride (PVC) and a lumen for SSD, which
was performed intermittently during 1-hour periods with
a 10-mL syringe; and Mallinckrodt™ Hi-Lo Tracheal Tube
(Mallinckrodt,) with a cylindrical-shaped cuff of PVC and
without a lumen for SSD.
No routine change of ventilator circuits was per-
formed. Tracheal suction when necessary was performed
using an open system and with strict barrier measures be-
fore airway management (hand washing, use of gloves and
face masks).
Oral cleansing was performed by nurses every 8 hours
as follows: first, the endotracheal cuff-pressure was tested
and oropharyngeal secretions were aspirated, then gauze-
impregnated with 20 mL of 0.12% chlorhexidine digluco-
nate, which was used to cleanse the teeth, tongue, and
mucosal surfaces, followed by the injection of 10 mL of
0.12% chlorhexidine digluconate into the oral cavity, and,
finally, after 30 seconds, the oropharyngeal area was
suctioned.
Semi-recumbent body position to maintain an angle of
40° was verified every 4 hours. Residual gastric volume
was verified every 6 hours (residual gastric volume lower
than 250 cc was considered acceptable). No selective di-
gestive decontamination was performed. Short-course
(2 days) systemic antibiotic therapy was administered to
patients with a decreased level of consciousness at the
time of intubation. The sedation drugs were adjusted to
achieve a level of 3 to 4 on the Ramsay scale [23].
Microbiological vigilance
Tracheal aspirate samples were obtained during endo-
tracheal intubation, then twice a week and finally on
extubation. Throat swabs were taken on admission to
ICU, then twice a week and at discharge from the unit.
Definitions
The diagnosis of pneumonia was established, as in a pre-
vious study by our team [24], when all of the following
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sputum; b) body temperature >38°C or <35.5°C; c) white
blood cell count >10,000/mm3 or <4,000/mm3; d) chest
radiograph showing new or progressive infiltrates; and e)
significant quantitative culture of respiratory secretions
by tracheal aspirate (>106 cfu/mL). The criteria for diag-
nosis of tracheobronchitis were the same as those for
pneumonia, but without change demonstrated on the
chest radiograph.
Pneumonia was considered as VAP when it was diag-
nosed after 48 hours of mechanical ventilation. The diag-
nosis of VAP was made by an expert panel blinded to
cuff-pressure system. VAP was considered as early onset
when it was diagnosed during the first 4 days of mechan-
ical ventilation. VAP was considered as late onset when it
was diagnosed after 4 days of mechanical ventilation.
VAP was classified pathogenically, according to throat
flora, as primary endogenous, secondary endogenous or
exogenous [25]. VAP was considered as primary en-
dogenous when caused by microorganisms already present
in the patient’s oropharyngeal flora on admission to ICU.
VAP was considered as secondary endogenous when
caused by microorganisms not found on admission but de-
tected in the patient’s oropharyngeal flora during the ICU
stay. VAP was considered as exogenous when it was caused
by microorganisms that were never carried in the patient’s
oropharyngeal flora.
Variables recorded
The following variables were recorded for each patient:
sex; age; diagnostic group; type of admission; smoking
status; chronic obstructive pulmonary disease; diabetes
mellitus; use of chemotherapeutic agents or steroid agents;
hematological tumor; solid tumor; diagnosis group; Acute
Physiology and Chronic Health Evaluation (APACHE)-II
score [26]; duration of mechanical ventilation; antibiotics
prior to VAP onset; use of paralytic agents; tracheotomy;
reintubation; enteral nutrition; type of endotracheal-tube
cuff-pressure control system (continuous or intermittent);
type of endotracheal tube (with or without a small-bore
lumen for SSD); positive end-expiratory pressure (PEEP);
Ramsay scale [23]; head-of-bed angle elevation; red blood
cell transfusion; cuff pressure; and ICU mortality.
Statistical analysis
Quantitative variables are reported as mean ± SD, and
were compared using the Student t-test. Qualitative vari-
ables are reported as frequency and percentage, and
were compared using the Chi-squared test and (in the
case of small samples) the Fisher exact test. We used the
Kruskal-Wallis test for singly ordered row (R) x column
(C) tables to compare proportions of patients who re-
ceived the intermittent/continuous cuff-pressure control
system in the diagnostic group, type of admission andstress-ulcer prophylaxis. The probability of remaining
VAP-free was represented using the Kaplan-Meier method
and comparison between the two groups was performed
with the log-rank test.
Multivariate logistic regression analysis (MLRA) was
used to assess the risk of VAP and the variables included
were: type of endotracheal-tube cuff-pressure control
system (continuous or intermittent); type of endotracheal
tube (with or without a small-bore lumen for SSD);
APACHE-II score; use of paralytic agents; reintubation;
enteral nutrition; duration of mechanical ventilation; and
the interaction between the type of endotracheal-tube
cuff-pressure control system (continuous or intermittent)
and endotracheal tube (with or without SSD). The magni-
tude of the effect was expressed as the odds ratio (OR)
and 95% CI.
Cox proportional hazard regression analysis using the
step-by-step method to select the predictor variables
was used, with VAP-free time as the dependent variable,
VAP as the event, and the type of endotracheal-tube
cuff-pressure control system (continuous or intermit-
tent) as the main independent variable, and controlling
for the APACHE-II score, use of paralytic agents, reintu-
bation, enteral nutrition, type of endotracheal tube (with
or without a small-bore lumen for subglottic secretion
drainage) and the interaction between type of endo-
tracheal cuff-pressure control system (continuous or
intermittent) and endotracheal tube (with or without
subglottic secretion drainage). The magnitude of the
effect was expressed as the hazard ratio (HR) and 95%
CI. In both regression analyses we introduced those
variables found to be associated with the risk of VAP
[27]. As the number of patients with VAP was 48, we
only included seven variables in the regression analyses
to avoid an over-fitting effect. A P-value <0.05 was consid-
ered statistically significant. For statistical analyses, we
used SPSS 17.0.1 (SPSS Inc., Chicago, IL, USA) and
StatXact 5.0.3 (Cyrus Mehta and Nitin Patel, Cambridge,
MA, USA).
Results
There were no significant differences between the two
groups of patients (150 with the intermittent and 134
with continuous cuff-pressure control system) in terms
of sex, age, smoking status, chronic obstructive pulmon-
ary disease, diabetes mellitus, chemotherapeutic agents,
steroid agents, hematological tumor, solid tumor, diag-
nosis group, APACHE-II score, duration of mechanical
ventilation, antibiotics prior to VAP onset, use of para-
lytic agents, tracheotomy, reintubation, enteral nutrition,
SSD or ICU mortality (Table 1). However, we found a higher
incidence of VAP (22.0% versus 11.2%; P= 0.02) and a higher
percentage of pressure-cuff determinations <20 cm H20
(9.32 ± 8.46 versus 0.00; P < 0.001) in the group of patients
Table 1 Characteristics of intermittent and continuous endotracheal-tube cuff-pressure control system patient groups
Intermittent cuff-pressure
control system (n = 150)
Continuous cuff-pressure
control system (n = 134)
P-value
Sex, female, n (%) 63 (42.0) 46 (34.3) 0.22
Age, years, mean ± SD 63.21 ± 14.99 59.61 ± 17.22 0.06
Diagnostic group, n (%) 0.81
Cardiac surgery 26 (17.3) 20 (14.9)
Cardiology 13 (8.7) 16 (11.9)
Respiratory 37 (24.7) 30 (22.4)
Digestive 23 (15.3) 20 (14.9)
Neurologic 26 (17.3) 21 (15.7)
Trauma 17 (11.3) 22 (16.4)
Others 8 (5.3) 5 (3.7)
Type of admission, n (%) 0.44
Postoperative 41 (27.3) 40 (29.9)
Medical 91 (60.7) 72 (53.7)
Traumatic 18 (12.0) 22 (16.4)
Smoker, n (%) 30 (20.0) 30 (22.4) 0.66
Chronic obstructive pulmonary
disease, n (%)
22 (14.7) 20 (14.9) 0.99
Diabetes mellitus, n (%) 45 (30.0) 40 (29.9) 0.99
Chemotherapeutic agents, n (%) 4 (2.7) 5 (3.7) 0.74
Steroid agents, n (%) 8 (5.3) 4 (3.0) 0.39
Hematological tumor, n (%) 6 (4.0) 5 (3.7) 0.99
Solid tumor, n (%) 16 (10.7) 18 (13.4) 0.58
APACHE-II score, mean ± SD 17.53 ± 8.88 17.57 ± 7.26 0.97
Intubation in the ICU, n (%) 48 (32.0) 42 (31.3) 0.99
Subglottic secretion drainage, n (%) 65 (43.3) 53 (39.6) 0.55
Tracheotomy, n (%) 25 (16.7) 29 (21.6) 0.29
Paralytic agents, n (%) 24 (16.0) 19 (14.2) 0.74
Enteral nutrition, n (%) 103 (68.7) 88 (65.7) 0.61
Antibiotics before VAP, n (%) 144 (96.0) 132 (98.5) 0.29
Reintubation, n (%) 16 (10.7) 16 (11.9) 0.85
Stress ulcer prophylaxis, n (%) 0.11
Proton-pump inhibitors 137 (91.3) 126 (94.0)
Histamine H-2 blockers 5 (3.3) 0
None 8 (5.3) 8 (6.0)
PEEP, cm H20, mean ± SD 5.25 ± 0.88 5.19 ± 0.85 0.56
Ramsay scale, mean ± SD 3.37 ± 0.83 3.45 ± 0.79 0.44
Head of bed angle elevation, degrees,
mean ± SD
33.13 ± 7.22 33.54 ± 7.65 0.64
Red blood cell transfusion, n (%) 52 (34.7) 54 (40.3) 0.39
Pcuff determinations < 20 cm H20, %,
mean ± SD
9.32 ± 8.46 0 <0.001
Pcuff determinations 20 to 30 cm H20, %,
mean ± SD
86.93 ± 10.07 100 <0.001
Pcuff determinations >30 cm H20, %,
mean ± SD
3.74 ± 4.85 0 <0.001
Lorente et al. Critical Care 2014, 18:R77 Page 4 of 8
http://ccforum.com/content/18/2/R77
Table 1 Characteristics of intermittent and continuous endotracheal-tube cuff-pressure control system patient groups
(Continued)
VAP, patients, n (%) 33 (22.0) 15 (11.2) 0.02
Tracheobronchitis, patients, n (%) 10 (6.7) 5 (3.7) 0.30
VAP or tracheobronchitis, patients, n (%) 43 (28.7) 20 (14.9) 0.01
Time of MV free of VAP, days, mean ± SD 10.31 ± 10.56 12.75 ± 14.05 0.10
Duration of MV, days, mean ± SD 15.65 ± 20.78 15.21 ± 15.23 0.84
ICU mortality, patients, n (%) 55 (36.7) 51 (38.1) 0.90
APACHE, acute physiology and chronic health evaluation; PEEP, positive end-expiratory pressure; MV, mechanical ventilation; VAP, ventilator-associated
pneumonia; Pcuff, cuff pressure.
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pressure control system. Compliance with the cuff-pressure
control system was 100% in both patient groups and there
were no cases of crossover.
Multivariate logistic regression analysis showed that
the continuous pressure control system (OR = 0.45, 95%
CI = 0.22, 0.89, P = 0.02) and the use of an endotracheal
tube incorporating a lumen for subglottic secretion
drainage (OR = 0.39; 95% CI = 0.19, 0.84; P = 0.02) were
protective factors against VAP (Table 2). However, the
interaction between type of endotracheal cuff-pressure
control system (continuous or intermittent) and endo-
tracheal tube (with or without SSD) was not statistically
significant (OR = 0.41, 95% CI = 0.07, 2.37; P = 0.32).
Multivariate Cox regression analysis showed that the con-
tinuous pressure control system (HR= 0.45, 95% CI = 0.24,
0.84, P= 0.01) and the use of an endotracheal tube incorpor-
ating a lumen for SSD (HR = 0.29, 95% CI = 0.15, -0.56,
P <0.001) were protective factors against VAP (Table 3).
However, the interaction between type of endotracheal
cuff-pressure control system (continuous or intermit-
tent) and endotracheal tube (with or without SSD) was
not statistically significant (HR = 0.35, 95% CI = 0.06,
1.84, P = 0.21).
Kaplan-Meier analysis showed a lower incidence of VAP
with continuous compared to intermittent cuff-pressureTable 2 Mutilple logistic regression analysis to predict
ventilator-associated pneumonia




0.45 0.22, 0.89 0.02
Endotracheal tube with versus
without a lumen for subglottic
secretion drainage
0.39 0.19, 0.84 0.02
APACHE-II score 0.98 0.94, 1.02 0.25
Paralytic agents 1.42 0.59, 3.41 0.43
Reintubation 2.29 0.91, 5.78 0.08
Enteral nutrition 2.17 0.98, 4.83 0.06
Days of mechanical ventilation 0.98 0.94, 1.02 0.23
APACHE, acute physiology and chronic health evaluation.control system (log rank = 6.60, P = 0.01, HR = 2.16, 95%
CI = 1.226, 3.803) (Figure 1).
Table 4 shows the microorganisms responsible for
VAP according to intermittent and continuous cuff-
pressure control systems. For statistical analysis, we
grouped the microorganisms responsible for VAP into
three groups: gram-positive bacteria, enterobacteriaceae
and non-fermentative gram-negative bacteria (Pseudomonas
aeruginosa, Acinetobacter baumanii and Stenotrophomonas
maltophilia). There were no significant differences between
patient groups in microorganisms responsible for VAP
(P = 0.52). Gram-positive bacteria, enterobacteriaceae and
non-fermentative gram-negative bacteria in the intermit-
tent cuff-pressure control system group were identified in
6 (18.2%), 18 (54.5%) and 9 (27.3%) cases of VAP, respect-
ively, versus 2 (13.3%), 10 (66.7%) and 3 (20.0%) cases of
VAP, respectively, in the continuous cuff-pressure control
system group.
There were no significant differences between patient
groups in VAP pathogenesis (P = 0.73). Primary endogen-
ous, secondary endogenous and exogenous VAP in the
intermittent cuff-pressure control system group were re-
corded in 8 (24.2%), 24 (72.7%) and 1 (3.0%) patients,
respectively, versus 2 (13.3%), 13 (86.7%) and none, re-
spectively, in the continuous cuff-pressure control sys-
tem group.Table 3 Cox regression analysis to predict ventilator-
associated pneumonia





Endotracheal tube with versus
without a lumen for subglottic
secretion drainage
0.29 0.15-0.56 <0.001
APACHE-II score 0.98 0.94-1.02 0.33
Paralytic agents 0.95 0.45-2.02 0.90
Reintubation 1.48 0.71-3.10 0.30
Enteral nutrition 1.41 0.69-2.90 0.35
APACHE, acute physiology and chronic health evaluation.
Figure 1 Cumulative proportion of patients remaining free of
ventilator-associated pneumonia using a continuous or
intermittent endotracheal tube cuff-pressure control system.
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groups in VAP onset (P = 0.99). Early and late onset VAP
in the intermittent cuff-pressure control system group
were recorded in 13 (39.4%) and 20 (60.6%) patients, re-
spectively, versus 6 (40.0%) and 9 (60.0%), respectively,








TOTAL gram-positive bacteria 6 2
MSSA 4 0
MRSA 1 1
Streptococcus pneumoniae 1 1
TOTAL gram-negative bacteria 27 13
Escherichia coli 0 4
Klebsiella spp. 2 0
Enterobacter spp. 5 1
Serratia marcescens 5 1
Morganella morganii 1 0
Proteus spp. 0 1
Citrobacter koseri 2 1
HaemophiIus influenzae 3 2
Pseudomonas aeruginosa 6 3
Stenotrophomonas maltophilia 2 0
Acinetobacter baumanii 1 0
TOTAL 33 15
(MSSA, methicillin-sensitive Staphylococcus aureus; MRSA, methicillin-resistant
Staphylococcus aureus).Discussion
In this study, we found a significant reduction in the inci-
dence of VAP with the use of a continuous endotracheal
tube cuff pressure control system. To our knowledge, this
is the largest study to date on the incidence of VAP com-
paring a continuous and an intermittent cuff-pressure
control system.
Previously, two RCTs of small sample size analyzed
the use of a continuous or an intermittent cuff-pressure
control system [10,11]. In the study by Valencia et al.,
which included 142 mechanically ventilated patients, the
authors found no significant differences in VAP rate be-
tween the groups (continuous versus intermittent cuff-
pressure control system) (29% versus 22%; P = 0.44) [10].
The RCT by Nseir et al., including 122 patients expected
to receive mechanical ventilation for at least 48 hours,
found that the group of patients receiving the continu-
ous compared to the intermittent cuff-pressure control
system showed a lower rate of VAP (9.8 versus 26.2%;
P = 0.03) [11]; however, regression analysis controlling
for confounders was not reported. In our study, regression
analysis showed that the use of a continuous endotracheal-
tube cuff-pressure control system was associated with a
significantly lower risk of VAP. The significance result on
regression analysis in our study may be due to the higher
sample size (n = 284) and to the patients included (patients
undergoing mechanical ventilation during more than
48 hours). The benefit of the continuous in compari-
son to the intermittent cuff-pressure control system to
reduce the risk of VAP could be due to a lower risk of
deflated cuff pressure (determined by a lower percent-
age of determinations of cuff pressure lower than 20 cmH20).
Thus, more constant maintenance of cuff pressure above
20 cm H20 with a continuous system could lead to a lower
risk of the progression of subglottic secretions into the lower
respiratory tract and finally of VAP. In addition, we found
that the use of an endotracheal tube with a small-bore lumen
for SSD exerted a protective effect against VAP; this finding
is consistent with the results of previous studies [20-22]. As
an interaction effect between SSD and the continuous endo-
tracheal tube cuff-pressure control system was not found,
we recommend both preventive measures in patients requir-
ing more than 48 hours of mechanical ventilation to reduce
the incidence of VAP and to increase VAP-free time.
Our study has certain limitations. First, the patients
were not randomly assigned to receive one or the other
cuff-pressure control system (continuous or intermittent).
However, the method of ICU cubicle allocation intro-
duced an element of chance: patients were admitted to
the first free cubicle available. Importantly, there were no
significant differences between the two groups in baseline
characteristics. Second, we did not perform an assessment
of pulmonary aspiration and tracheal mucosal damage.
Third, the study was performed in a single ICU, and the
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Fourth, regarding the blinding process, continuous or
intermittent endotracheal tube cuff-pressure control sys-
tems are visually different; thus, the study could not be
blinded for the attending physicians. Finally, the use of an
endotracheal tube with a lumen for SSD was based on
availability in the hospital due to financial constraints;
thus, the tube with SSD was only used in 41.5% of all pa-
tients. However, due to this limitation, we were able to
analyze the impact of the continuous control of cuff pres-
sure and an endotracheal tube with a lumen for SSD on
the incidence of VAP.
However, our study also has certain strengths. First,
this is the largest study to date on the incidence of VAP
comparing endotracheal-tube cuff-pressure control sys-
tems (continuous versus intermittent), including 284 pa-
tients in comparison to 122 [11] and 142 patients [10] in
previous studies. Second, we found a lower incidence of
VAP with the use of a continuous cuff-pressure control
system in the MLRA, not only in the Kaplan-Meier ana-
lysis as in the study by Nseir et al. [11]. Third, the type
of system for cuff-pressure control (continuous or inter-
mittent) and the type of endotracheal tube (with or with-
out a lumen for SSD) were blinded for the expert panel
that established the diagnosis of VAP. Lastly, microbio-
logical vigilance was based on tracheal aspirate and throat
swabs twice a week and we found no differences in the
pathogenesis or the microorganisms responsible for VAP
between the groups receiving either continuous or inter-
mittent cuff-pressure control.
Current guidelines on the prevention of VAP do not
contain recommendations for the use of a continuous or
an intermittent endotracheal-tube cuff-pressure control
system [12-19]. Thus, despite the limitations of our study,
our findings could help in decision-making on VAP pre-
vention measures. They support the use of a continuous
endotracheal-tube cuff-pressure control system.
Conclusion
The use of a continuous endotracheal cuff-pressure con-
trol system and/or an endotracheal tube with a lumen
for SSD could help to prevent VAP in patients requiring
more than 48 hours of mechanical ventilation.
Key messages
 The use of a continuous endotracheal cuff-pressure
control system and/or an endotracheal tube with a
lumen for SSD could help to prevent VAP in patients
requiring more than 48 hours of mechanical ventilation.
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